In addition, IGF-1R antibodies and small molecule inhibitors have been investigated as therapy for other malignancies, including breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, leukemia, and rhabdomyosarcoma [101]. This evidence concerns the gene IGF1R and rhabdomyosarcoma.